Generics Bill Seeks Faster Access, Improved Safety

Published Online: Thursday, June 14, 2012
Follow Pharmacy_Times:

A bill that would speed up approval of generic vaccines and biosimilar products has been forwarded to the House of Representatives floor, according to an article in the Pittsburgh Post Gazette.

The action follows a unanimous vote by the House’s Energy and Commerce Subcommittee held May 10, 2012. Sponsored by Representative Tim Murphy (R, PA), the bill is part of the FDA Reform Act, which includes the Prescription Drug User Fee Act, Generic Drug User Fee Act, and Medical Device User Fee Act. The acts either reauthorized several FDA programs relating to medical devices or created new programs to put generics on the market faster.

“When we set out on creating a generic drug program, we had one goal: to make cost effective, lifesaving medications more available and accessible,” Rep. Murphy said in a press release. “(This) legislation accomplishes that goal and levels the playing field for U.S. manufacturers by establishing one quality standard for all drugs sold in the United States.”

“The FDA Reform Act contains important metrics that will hold the FDA accountable for its performance, will help provide new therapies to our nation’s children, significantly improve scientific exchange at FDA’s advisory committees and ensure transparency and public input in the development of FDA’s guidance documents,” Fred Upton, chairperson for the Energy and Commerce Subcommittee, said in a release.

As part of the Generic Drug and Biosimilar User Fee Act, the generic drug industry would pay $1.5 billion over a 5-year period in exchange for faster reviews of generic drug applications, according to the House Energy and Commerce Committee’s bill fact sheet.

According to the Generic Pharmaceutical Association (GPhA), the additional funding allows the FDA’s Office of Generic Drugs to hire the additional personnel needed to approve generic drugs.

“With both the full House and Senate now set to consider these historic agreements, American consumers are one step closer to receiving faster access to low-cost, high-quality generic medicines,” Ralph G. Neas, president and chief executive of GPhA, said in a press release.

In addition, the bill would require the FDA to conduct more frequent inspections of foreign drug manufacturing plants, according to the Pittsburgh Post Gazette. Current regulations call for inspections at foreign plants once every 9 years. Domestic plants are inspected every other year, and the provision attempts to close that gap, according to Rep. Murphy’s website.

A portion of the $1.5 billion will be used for the generic manufacturer facility inspections, GPhA stated. The inspection measures, coupled with the expedited approvals, improve access to medications while also safeguarding quality. The programs were developed in conjunction with GPhA, the FDA, and other stakeholders.

The House of Representatives has not yet determined when the bill will be presented on the House floor.



Related Articles
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$